Key terms

About DGX

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DGX news

Feb 26 9:34am ET Moderna downgraded, Gap upgraded: Wall Street’s top analyst calls Feb 26 6:12am ET Quest Diagnostics initiated with a Market Perform at Leerink Feb 21 8:07am ET Quest Diagnostics and Instacart announce collaboration Feb 08 7:38am ET Piper Sandler Remains a Hold on Quest Diagnostics (DGX) Feb 08 7:34am ET Quest Diagnostics price target raised to $145 from $140 at Piper Sandler Feb 07 10:32am ET Amgen downgraded, Enphase upgraded: Wall Street’s top analyst calls Feb 07 5:03am ET Quest Diagnostics upgraded to Buy from Hold at Jefferies Feb 02 8:52am ET Quest Diagnostics price target lowered to $125 from $140 at Deutsche Bank Feb 02 8:30am ET Quest Diagnostics price target lowered to $145 from $150 at Truist Feb 02 6:49am ET Quest Diagnostics price target lowered to $150 from $165 at Mizuho Feb 02 6:46am ET Quest Diagnostics price target lowered to $136 from $140 at Baird Feb 02 5:41am ET Analysts Are Bullish on These Healthcare Stocks: Quest Diagnostics (DGX), Becton Dickinson (BDX) Feb 02 5:37am ET Quest Diagnostics price target lowered to $138 from $145 at Barclays Feb 02 3:37am ET Barclays Keeps Their Hold Rating on Quest Diagnostics (DGX) Feb 01 8:51pm ET Quest Diagnostics price target lowered to $135 from $145 at Citi Feb 01 8:20pm ET Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Sarepta Therapeutics (SRPT) and Regeneron (REGN) Feb 01 7:13am ET Quest Diagnostics increases quarterly dividend 5.6% to 75c per share Feb 01 7:11am ET Quest Diagnostics sees FY24 adjusted EPS $8.60-$8.90, consensus $8.99 Feb 01 7:10am ET Quest Diagnostics reports Q4 EPS $2.15, consensus $2.11 Jan 31 8:25pm ET Notable companies reporting before tomorrow’s open Jan 31 12:59pm ET Notable companies reporting before tomorrow’s open Jan 25 6:16am ET Quest Diagnostics price target lowered to $152 from $153 at JPMorgan Jan 17 8:59am ET Quest Diagnostics and Fitbit announce collaboration to study wearable devices Jan 10 5:39am ET Quest Diagnostics: A Buy Rating Backed by Stable Pricing and Strategic Acquisitions Jan 08 8:57am ET Quest Diagnostics acquires assets of Steward Health Care’s outreach lab services Jan 08 7:24am ET Quest Diagnostics unit, Alliance Foundation Trials enter collaboration Jan 02 5:04pm ET Quest Diagnostics initiated with an Equal Weight at Barclays Dec 20 9:55am ET Quest Diagnostics price target raised to $150 from $145 at Truist Dec 20 7:36am ET Quest Diagnostics names Yuri A. Fesko, M.D., as Chief Medical Officer Dec 19 4:55am ET Quest Diagnostics management to meet with Truist Dec 13 6:49am ET Quest Diagnostics price target raised by $4 at JPMorgan, here’s why

No recent news articles are available for DGX

DGX Financials

1-year income & revenue

Key terms

DGX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DGX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms